Long Term Responses To Rigosertib In Lower-Risk Myelodysplastic Syndromes (Mds) Patients

A fraction of lower risk MDS patients benefit from approved therapies but generally for a limited duration, and several require experimental therapies.1 Rigosertib, a small molecule inhibitor of RAS effector pathways, has been tested in phase I and II trails at our center. We present case histories of two patients with lower-risk MDS who experienced a complete response to Rigosertib which persisted for more than five years.